RESOURCES
-
-
-
June 23, 2025
Semaglutide and Lisinopril Exerts Therapeutic Benefits in a Genetically Engineered Diabetic Nephropathy Mouse Model
Diabetic nephropathy (DN) is a major driver of chronic kidney disease, yet preclinical models often fail to replicate human disease severity. GemPharmatech addresses this by developing an improved translational DN mouse model that mimics progressive human kidney damage—enabling better evaluation of future therapies.
-
-
-
-
June 23, 2025
A Persistent Hypertension Model Developed on the AGT Humanized Mice
Hypertension, a major metabolic syndrome condition, has experienced a rapid increase in global prevalence. AGT (angiotensinogen), the key precursor in the RAAS pathway, serves as a prime target for RNAi therapies. GemPharmatech has developed an AGT humanized mouse model to advance hypertension research and developed a modified human RENIN virus to induce sustained high blood pressure in these mice.
-
-
-
-
June 18, 2025
Development of Preclinical Models for the Evaluation of Conventional and in vivo CAR-T Therapies
Traditional CAR-T therapies require expensive, complex ex vivo T-cell engineering. While in vivo CAR-T generation using lentiviral vectors offers a faster, cheaper alternative, preclinical testing is limited by graft-versus-host disease (GVHD) in immunodeficient mouse models. To overcome this, GemPharmatech developed the NCG-MHC-dKO mouse, featuring dual MHC I/II knockout to minimize GVHD while maintaining human immune cell engraftment. Testing an anti-CD19 CAR lentiviral vector in this model demonstrated successful in vivo CAR-T generation and potent tumor suppression, with no significant GVHD. The NCG-MHC-dKO model enables reliable, long-term evaluation of in vivo CAR-T therapies, enhancing translational research.
-
-
-
-
June 18, 2025
NCG-X: A Novel Mouse Model For Preclinical Studies Evaluating Humanized Erythroid Reconstitution
Hematopoietic stem cell (HSC) transplantation is critical for treating blood cancers and autoimmune diseases, but existing animal models rely on toxic preconditioning (irradiation/chemotherapy), leading to off-target effects that undermine research validity. To overcome this, we developed the NCG-X mouse by introducing a C-KIT (Val831Met) mutation into the NCG mouse. This model enables human HSC engraftment without irradiation or chemoablation, offering a promising platform for immune and erythroid reconstitution studies.
-
-
-
-
June 16, 2025
Applications for SLE patient-derived PBMC-induced mouse model in preclinical pharmacological studies
To advance Systemic lupus erythematosus (SLE) research, GemPharmatech has developed a humanized SLE mouse model by transferring PBMCs from SLE patients into immunodeficient mice (NCG mice). This model replicates key disease features, including high levels of human auto-antibodies and renal immune complex deposition. Furthermore, this model responds to B-cell targeted therapeutic antibodies, demonstrating its utility in evaluating novel therapeutic modalities.
-
-
-
-
May 18, 2025
Repurposing Oncology Drugs to Treat Autoimmune Diseases
Developing new drugs requires a significant investment of time and economic costs. Drug repurposing therefore has significant advantages over developing new drugs. Humanized SLE models exhibit similar pathological features to those seen in patients with SLE, such as high levels of auto-antibodies and pathogenic B cells, and respond positively to treatment with potentially repurposed oncology therapeutics. As such, these models are valuable for the evaluation of other future repurposed B cell-directed oncology drugs.
-
-
-
-
May 01, 2025
AACR 2025 Poster Resources
Our nine AACR 2025 posters are now available for download!
-
-
-
-
December 20, 2024
Mouse Models of anti-PD-1 Resistance Reveals Insights into Resistance Mechanisms
The immune checkpoint molecule PD-1 and its ligand PD-L1 play a pivotal role in tumor immune evasion and progression by thwarting apoptosis induced by the immune system. Despite the significant efficacy of anti-PD-1/PD-L1 therapy against solid tumors, durable responses are observed in only a minority of patients. Many patients fail to experience the full benefits of therapy, with a notable proportion eventually developing acquired resistance. Therefore, establishing robust preclinical models of PD-1 resistance is crucial for unraveling resistance mechanisms and devising novel treatment strategies. Common mechanisms contributing to anti-PD-1/anti-PD-L1 resistance include the absence of suitable tumor antigens, tumor surface MHC molecules inactivation, dysregulated IFN-γ signaling pathways, and the immunosuppressive tumor microenvironment.
-
-
-
-
December 08, 2024
Spontaneous Systemic Lupus Erythematosus Mouse Model Based on TLR7Y264H Genetic Mutation
Toll-like receptor 7(TLR7) variant Y264H has recently been identified to cause Systemic Lupus Erythematosus (SLE) in human patients. Mice harboring TLR7Y264H mutation in the C57BL/6NCrL background developed spontaneous SLE-like symptoms and organ damage. In order to create clinically relevant mouse models of SLE to evaluate novel therapeutics (especially targeting TLR7), we developed TLR7Y264H mutant mice in both the BALB/c and C57BL/6J background.
-